No Picture
PR Newswire

Forge Therapeutics to Present at the BIOCOM Global Life Science Partnering Conference

SAN DIEGO, Feb. 18, 2016 /PRNewswire/ — Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, announced today that Zachary Zimmerman, Ph.D., Chief Executive Officer, will present a corporate overview at the BIOCOM Life Science Partnering Conference being held at the Lodge at Torrey Pines, San Diego, CA on February 24th & 25th, 2016. 

“It is an honor to be selected to present at this prestigious partnering conference that attracts life science executives from around the globe to visit San Diego and become inspired by our vibrant biotech ecosystem,” said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics.  “This is a great opportunity to showcase the Forge technology and our leading efforts in Gram-negative bacteria where we have developed the first non-hydroxamate inhibitor of LpxC that is potent in cells, including multi-drug resistant superbugs, and efficacious in vivo.” 

The presentation will include an overview of Forge’s metalloprotein technology platform, lead therapeutic programs in Gram negative bacteria, epigenetics, and cancer immunity, as well as financing and partnering strategies.

Details of Forge’s presentation:


BIOCOM Life Science Partnering Conference


Wednesday, February 24th


10:40 AM PST


Alfred Mitchell Room


About Forge Therapeutics, Inc.

Forge Therapeutics, Inc. (“Forge”) is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit

About BIOCOM Global Life Science Partnering Conference

In its 6th Year, the BIOCOM Global Life Science Partnering Conference is an exclusive partnering forum that provides senior executives, bankers, venture capitalists, and business development professionals from the leading pharmaceutical and biotech companies to network and do business with one another from around the globe.  To learn more please visit


Logo –


SOURCE Forge Therapeutics, Inc.


No Picture
PR Newswire

OncoSec to Host Second Quarter Financial Results Conference Call on March 8, 2016

SAN DIEGO, Feb. 18, 2016 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal second quarter 2016 financial results conference call on Tuesday, March 8 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial (877) 731-1960 and use conference ID number: 50125992. An archived version of the presentation will be available for 90 days on the “Investors” section of OncoSec’s website:

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer.  ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit

Mary Marolla
OncoSec Medical Incorporated

Logo –


SOURCE OncoSec Medical Incorporated


No Picture
PR Newswire

ViaCyte to Present at Upcoming Healthcare Events

SAN DIEGO, Feb. 17, 2016 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.

Details of the presentations are as follows:


Regenerative Medicine: Transitioning Therapeutics from Cells to the Clinic


Development of Stem-Cell Derived, Macroencapsulated Islet Replacement for Type 1 Diabetes


Dr. Thomas Schulz, Director, ES Cell Technology


February 22, 2:35 p.m. EST


New York Academy of Sciences Conference Center, New York, NY


The 2nd Saudi International Biotechnologies Conference 2016


Chasing a Cure for Type 1 Diabetes: The Development of a Stem Cell Derived Islet Replacement Therapy


Dr. Paul Laikind, President and CEO


February 23, 9:15 a.m. AST


KACST Headquarters, Conference Hall, Riyadh, Saudi Arabia


American Society of Transplantation: Pipeline Presenters


Dr. Kevin D’Amour, Vice President, Research and CSO


February 25, 11:00 a.m. MST


Arizona Biltmore, Phoenix, Arizona

ViaCyte’s VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes.  More info on the clinical trial is here:

For more information about ViaCyte’s participation in industry events, please visit:

About ViaCyte

ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goal of reducing the risk of hypoglycemia and diabetes-related complications without requiring long-term immune suppression. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

For more information please visit  Connect with ViaCyte here: and

Logo –


SOURCE ViaCyte, Inc.


No Picture
PR Newswire

MemorialCare Health System Announces Dialysis Joint Venture Partnership with Fresenius Medical Care in Southern California

Portfolio of 15 clinics offers integrated, patient-centered dialysis care

ORANGE and LOS ANGELES Counties, Calif., Feb. 16, 2016 /PRNewswire-USNewswire/ — MemorialCare Health System announced today that it has entered into a joint venture partnership with Fresenius Medical Care North America to operate 15 dialysis clinics in Orange and Los Angeles counties. Thirteen of these clinics are fully operational and two additional clinics are being developed in San Juan Capistrano and Huntington Beach.

The partnership will provide comprehensive programs and services, including kidney dialysis treatment, medical services, patient and family support, wellness and prevention, disease management and continuity of health care services to ensure a high quality integrated care experience, while increasing access to community clinics throughout the Southland.

Fresenius Medical Care, the world’s largest integrated provider of services for patients with chronic kidney failure, cares for more than 170,000 people with end stage renal disease at over 2,200 dialysis clinics around the country. 

“This is a major step forward in MemorialCare’s strategy and commitment to the community to improving the health and health care of those we serve by offering a full complement of integrated services across our wide and expanding geographic coverage area,” says Barry Arbuckle, PhD, president & CEO of MemorialCare Health System. “Broadening our integrated system to cover all aspects of the care continuum—from wellness and prevention to diagnosis, treatment and rehabilitation—allows us to ensure our patients receive convenient access to high quality and seamless coordination of care across our health system.”

One of the nation’s top nonprofit integrated delivery systems, MemorialCare has 15,000 employees, physicians and volunteers; six hospitals; and more than 200 care locations in Southern California, including ambulatory surgery centers, imaging facilities, urgent care centers, Seaside Health Plan and countless programs and services.

“For MemorialCare, being responsive to the needs of our communities has resulted in the expansion of our services and transformation of the way we deliver care,” adds Mark Schafer, MD, CEO of MemorialCare Medical Foundation, which includes more than 2,000 physicians associated with MemorialCare Medical Group and Greater Newport Physicians IPA. “This new partnership to provide extensive and far-reaching kidney dialysis services across the continuum of care is vital to our ability to provide the comprehensive, affordable, integrated care that is MemorialCare’s hallmark.”

“In addition to providing what our patients and community need today, Fresenius Medical Care has the research and development infrastructure and capabilities to prepare us for innovations and patient care enhancements that will benefit our patients in the future, including increased utilization of home-based dialysis,” adds James Leo, M.D., chair of MemorialCare Physician Society, representing 2,000 physicians from throughout Southern California who drive clinical outcomes and performance for MemorialCare. “As physicians, we are thrilled with the opportunity to engage in new and emerging technologies, techniques and treatments.”

The Fresenius Medical Care clinics offer traditional in-center dialysis in locations close to where the community lives and works, as well as access to regional home dialysis programs, which allows patients to perform treatments at home and on their own schedule while receiving comprehensive care and support. The clinics also offer other dialysis patient-centered services, including a kidney transplant support program, vascular care, anemia management, nutrition counseling, bone disease management and social worker support.

“We are excited to be partnering with MemorialCare to continue advancing kidney care in Southern California,” said Ana Silveira, regional vice president for Fresenius Medical Care. “MemorialCare patients in these communities will be able to have a comprehensive, integrated care experience and receive a superior level of care that is consistent with our commitment to improve the quality of life of every patient, every day.”

Patient dialysis treatment clinics included in the joint venture include:

  • Fountain Valley Clinic: 17197 Newhope Street in Fountain Valley, (714) 241-0196)
  • Fountain Valley Home Dialysis Clinic: 17197 Newhope Street in Fountain Valley, (714) 778-0488
  • East First Tustin Clinic: 535 E 1st Street in Tustin, (714) 730-1428
  • Fresenius Medical Care Santa Ana Clinic: 2740 Bristol Street in Santa Ana, (714) 754-1670
  • Goldenwest – Westminster Clinic: 15330 Goldenwest Street in Westminster, (714) 373-1543
  • Laguna Canyon – Irvine Clinic: 16255 Laguna Canyon Road in Irvine, (949) 727-4495
  • Fresenius Medical Care Orange County Home Clinic: 1401 S Brookhurst Road in Fullerton, (714) 773-1407
  • Hospital Circle – Westminster Clinic: 290 Hospital Circle in Westminster, (714) 895-3698
  • Garden Grove Blvd. – Garden Grove Clinic: 12555 Garden Grove Blvd. in Garden Grove, (714) 741-7255
  • Harbor Blvd. – Garden Grove Clinic: 12761 Harbor Blvd. in Garden Grove, (714) 539-3122
  • Fresenius Medical Care Long Beach Clinic: 440 W Ocean Blvd. in Long Beach, (562) 432-4444
  • Fresenius Medical Care – Carson Community Clinic:  20710 Leapwood Ave. in Carson, (310) 323-8997
  • Fresenius Medical Care Norwalk Clinic: 13063 Rosecrans Ave. in Santa Fe Springs, (562) 404-7400

Dialysis, also known as renal replacement therapy, aims to replace the critical functions of the kidneys and sustain life in people with severe kidney failure. The majority of patients receive treatment in the in-center setting three times a week with each dialysis session lasting between three to five hours. Today, about 350,000 people in the United States use dialysis as a life-sustaining therapy.

MemorialCare Health System, a nonprofit Southern California integrated delivery system and pioneer in evidence-based medicine, has more than 200 care sites; 15,000 employees and affiliated physicians; six top hospitals—Long Beach Memorial, Miller Children’s & Women’s Hospital Long Beach, Community Hospital Long Beach, Orange Coast Memorial Medical Center in Fountain Valley and Saddleback Memorial Medical Center in Laguna Hills and San Clemente; MemorialCare Medical Group; Greater Newport Physicians (GNP); Seaside Health Plan; ambulatory surgery centers; and imaging, outpatient, kidney dialysis and urgent care facilities. Its many honors and recognition for its health care organizations include Best U S. Health Care Systems, 10 Largest U.S. Children’s Hospitals, Top 50 Hospitals, Straight A Hospital Safety Scores, Top 50 Cardiovascular Hospitals, and more. For information, visit

Fresenius Medical Care North America is the premier health care company focused on delivering the highest-quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, as well as the country’s largest practice of hospitalists and post-acute physicians, Fresenius Medical Care provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s only vertically integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit For information about patient services, visit



SOURCE MemorialCare


No Picture
PR Newswire

Pharmaceutical And Biotechnology Patent Expert John Doll Joins Viropro Board

Doll was former Acting Under Secretary of Commerce for Intellectual Property and Acting Commissioner of the United States Patent and Trademark Office

SAN JOSE, Calif., Feb. 16, 2016 /PRNewswire/ — Viropro, Inc. (OTCBB: VPRO), which has previously announced it will be changing its name to Axxiom, today announced that John Doll has agreed to join its Board of Directors effective immediately.

John Doll retired in October 2009 as Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office (USPTO), where he was responsible for advising the President, the Secretary of Commerce and the Administration about all intellectual property matters. John began his career at USPTO in 1974 as an assistant examiner, and progressed to be Director of Patent Examination responsible for all patent examination issues in the chemistry, chemical engineering, pharmaceutical, biotechnology and design art areas. Before that he was Supervisory Patent Examiner, having examined and supervised the examination of patent applications encompassing pharmaceuticals, herbicides, pesticides, dyestuffs, inorganic chemistry, hydrometallurgy, zeolite catalysts, buckministerfullerenes, proteins, and peptides. “We are delighted and honored to have someone of John’s stature, as a former commissioner of the United States Patent Office, join our Board,” said Dr. Ken Sorensen, Viropro Chairman of the Board. “His decades of experience as a career patent official who rose through the ranks to become the Head of the Office, and his leadership during some of the most formidable changes in the landscape of US and international patent law, will be invaluable to help guide the transformation of Viropro as we continue our efforts to build a world-class company.”

During his time at the USPTO, John won numerous awards for the implementation of the Patent Application Location and Monitoring (PALM) system, the development and implementation of the automated examiner Office Action tools, for establishing the Biotechnology Customer Partnership, and for the implementation of the Image File Wrapper system. “I am excited to join the Board of Viropro as we create a diversified life sciences company focusing on the development of high value therapeutic drugs and services,” Doll said.

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the company’s limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to execute the company’s future plans.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, visit 


SOURCE Viropro, Inc.


No Picture
PR Newswire

Tocagen Appoints John Wood as Vice President, Regulatory Affairs and Quality Assurance

SAN DIEGO, Feb. 16, 2016 /PRNewswire/ — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that John Wood has been named vice president of regulatory affairs and quality assurance. Mr. Wood holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need. While at IDEC Pharmaceuticals he played a leading role, in close collaboration with Genentech, in the first regulatory approval of RITUXAN® for the treatment of immune system B-cell malignancies.

“John holds extensive experience in regulatory affairs activities, including overseeing drug approvals by the FDA and international regulatory agencies,” said Harry Gruber, M.D., chief executive officer of Tocagen. “As Tocagen continues to enroll patients in Toca 5, our Phase 2/3 clinical trial in patients with recurrent high grade glioma, John’s expertise and insights will be extremely beneficial.”

Prior to joining Tocagen, Mr. Wood led regulatory affairs at Arena Pharmaceuticals, where he played an integral role interfacing with Eisai Inc. regarding regulatory strategy for life cycle management for BELVIQ®. Previous to this role Mr. Wood led regulatory affairs and alliance management at Amylin Pharmaceuticals, Inc., where he directed activities surrounding the first regulatory approvals of SYMLIN® and BYETTA® in the United States, served as program leader for BYETTA and acted as the primary interface with Eli Lilly. Prior to his position at Amylin Pharmaceuticals, Mr. Wood held regulatory leadership positions at Quintiles Consulting and Gensia, Inc. 

Mr. Wood holds a bachelor’s degree in biology from University of California, San Diego and is Regulatory Affairs Certified by the Regulatory Affairs Professionals Society (RAPS).

About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. For more information visit or follow @Tocagen.

Media Contact:
Monica May
Canale Communications


SOURCE Tocagen Inc.


No Picture
PR Newswire

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update

– Business update conference call and webcast on February 17, 2016 at 5:00 PM EST –

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 16, 2016 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced its financial results for the second quarter of the 2016 fiscal year ending December 31, 2015. The Company also highlighted recent corporate and clinical achievements and provided an overview of expected near-term milestones.

DelMar management will host a business update conference call and live webcast for investors, analysts and other interested parties on Wednesday, February 17, 2016, at 5:00 pm EST.

“The progress we continued to achieve this quarter for our VAL-083 (dianhydrogalactitol) clinical program and the consistent positive data from preclinical studies, along with the recently announced collaboration with University of Texas MD Anderson Cancer Center, not only further validates the promise of VAL-083 as a potential new treatment for chemo-resistant tumors, but also sets the stage for 2016 to be a transformational year for our Company,” stated Jeffrey Bacha, Chairman and CEO of DelMar Pharmaceuticals.


“For the first half of 2016 we will focus on accomplishing several actionable milestones that will position DelMar to expand clinical development around VAL-083 and also serve to maximize shareholder value. We believe that DelMar’s recent data, combined with historical clinical validation, positions VAL-083 as a superior alternative to currently available chemotherapy for GBM patients whose tumors are characterized by high expression of MGMT. Our goal is nothing short of creating a paradigm-shift in the treatment of this horrific cancer,” added Mr. Bacha.

“We anticipate reporting top-line survival data from the Phase II expansion cohort of our refractory GBM clinical trial in the first half of 2016. Based on our observations to date, we believe that we are well positioned to advance VAL-083 into Phase II/III registration clinical trials in refractory GBM during 2016. New non-clinical data reported in 2015 continued to demonstrate VAL-083’s unique cytotoxic anti-cancer mechanism, and we anticipate leveraging these data by expanding our clinical development programs around VAL-083 also during 2016,” concluded Mr. Bacha.


  • Report top-line data from the Phase II study with VAL-083 in refractory GBM in the first half of 2016;
  • Engage the U.S. Food and Drug Administration (FDA) regarding the design of a proposed registration-directed Phase II/III clinical trial for VAL-083 in refractory GBM;
  • Initiate registration-directed Phase II/III clinical trials for VAL-083 as a new treatment option for refractory GBM in 2016;
  • Initiate the Phase II clinical study at MD Anderson with VAL-083 in patients with GBM at first recurrence/progression;
  • Initiate clinical studies in newly-diagnosed GBM patients as an alternative to temozolomide in patients with high expression of MGMT;
  • Initiate new clinical trials with VAL-083 in refractory NSCLC;
  • Continue to pursue pre-clinical research with leading investigators to advance VAL-083 as a potential treatment for other chemo-resistant cancers including ovarian cancer and pediatric medulloblastoma;
  • Maximize the value of the VAL-083 pipeline through potential partnership opportunities in high value oncology markets;
  • Continue to build the Company’s intellectual property portfolio; and
  • Continue to implement strategies that enable DelMar to meet qualifications to list its shares on a national stock exchange.

DelMar plans to host a conference call on Wednesday, February 17, 2016, at 5:00 p.m. EST, to discuss quarterly results and provide a corporate update. For both “listen-only” participants and those who wish to take part in the question and answer portion of the call, the telephone Dial-in Number is (800) 895‑1715 (toll-free) or (785) 424‑1059 (toll) with Conference ID “DelMar.” A link to the webcast and slides will be available on the IR Calendar of the Investors section of the Company’s website at and will be archived for 30 days.

For the three months ended December 31, 2015 the Company reported a net loss of $2,646,690, or a net loss per share of $0.06, compared to a net loss of $619,633, or a net loss per share of $0.02 for the three months ended December 31, 2014 as restated.

The following represents selected financial information as of December 31, 2015. The Company’s financial information has been prepared in accordance with U.S. GAAP and this selected information should be read in conjunction with DelMar’s consolidated financial statements and Management’s Discussion and Analysis (MD&A), as filed.

DelMar’s financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the company’s website at:

Selected Balance Sheet Data 





June 30,



(as restated)

Cash and cash equivalents



Working capital



Total Assets



Derivative liability



Total stockholders’ equity (deficit)



Selected Statement of Operations Data

For the Three months Ended:  

December 31,



December 31,



(as restated)

Research and development



General and administrative



Change in fair value of derivative liability



Change in fair value of derivative liability due to change in warrant terms



Loss on exchange of warrants


Foreign exchange loss



Interest income



Net loss from operations



Basic weighted average number of shares outstanding



Basic loss per share




About VAL-083
VAL-083 is a “first-in-class,” small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of malignant gliomas.

DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar® (temozolomide).

DelMar recently announced the completion of enrollment in a Phase II clinical trial of VAL-083 in refractory GBM. Patients have been enrolled at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO).

In the Phase I dose-escalation portion of the study, VAL-083 was well tolerated at doses up to 40mg/m2 using a regimen of daily x 3 every 21 days. Adverse events were typically mild to moderate; no treatment-related serious adverse events reported at doses up to 40 mg/m2. Dose limiting toxicity (DLT) defined by thrombocytopenia (low platelet counts) was observed in two of six (33%) of patients at 50 mg/m2. Generally, DLT-related symptoms resolved rapidly and spontaneously without concomitant treatment, although one patient who presented with hemorrhoids received a platelet transfusion as a precautionary measure.

Sub-group analysis of data from the Phase I dose-escalation portion of the study suggested a dose-dependent and clinically meaningful survival benefit following treatment with VAL-083 in GBM patients whose tumors had progressed following standard treatment with temozolomide, radiotherapy, bevacizumab and a range of salvage therapies.

Patients in a low dose (≤5mg/m2) sub-group had a median survival of approximately five (5) months versus median survival of approximately nine (9) months for patients in the therapeutic dose (30mg/m2 & 40mg/m2) sub-group following initiation of VAL-083 treatment. DelMar reported increased survival at 6, 9 and 12 months following initiation of treatment with VAL-083 in the therapeutic dose sub-group compared to the low dose sub-group.

Further details can be found at

About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit; or contact DelMar Pharmaceuticals Investor Relations: / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+. Investor Relations Counsel:  Amato & Partners LLC.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

Logo –


SOURCE DelMar Pharmaceuticals, Inc.